<DOC>
	<DOCNO>NCT02164500</DOCNO>
	<brief_summary>The Purpose trial : - determine overall response rate ( ORR , complete response [ CR ] + partial response [ PR ] ) patient relapse refractory HL - determine safety profile ruxolitinib patient relapse refractory HL</brief_summary>
	<brief_title>JAK-inhibition Recurrent Classical Hodgkin Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<criteria>relapsed refractory HL ECOG &lt; = 2 , major organ dysfunction write informed consent history another primary malignancy â‰¤ 2 year female patient pregnant breast feeding patient know history HIV seropositivity chronic active hepatitis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>